
Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …

Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

